Sourcing Guide Contents
Industrial Clusters: Where to Source China Medicine Company
SourcifyChina Sourcing Report 2026
Subject: Deep-Dive Market Analysis – Sourcing Traditional Chinese Medicine (TCM) and Pharmaceutical Products from China
Prepared for: Global Procurement Managers
Date: January 2026
Author: Senior Sourcing Consultant, SourcifyChina
Executive Summary
China remains the world’s largest producer and exporter of Traditional Chinese Medicine (TCM) and pharmaceutical products, accounting for over 60% of global TCM supply. With a well-established supply chain, government support, and decades of manufacturing expertise, China offers competitive advantages in cost, scale, and product diversity. This report provides a strategic overview of key industrial clusters producing TCM and related pharmaceutical goods, with a comparative analysis of major production provinces to guide procurement decisions in 2026.
Note: “China medicine company” is interpreted as enterprises engaged in the research, manufacturing, and export of Traditional Chinese Medicine, herbal extracts, patent medicines, and integrated pharmaceutical products.
Key Industrial Clusters for TCM & Pharmaceutical Manufacturing in China
China’s TCM manufacturing is concentrated in regions with strong agricultural inputs (herbal cultivation), advanced biotech infrastructure, and government-backed industrial zones. The following provinces and cities dominate production:
| Region | Key Cities | Specialization | Key Advantages |
|---|---|---|---|
| Guangdong | Guangzhou, Foshan, Zhongshan | Patent TCM, TCM injectables, OTC herbal products | High R&D investment, strong export infrastructure, proximity to Hong Kong |
| Zhejiang | Hangzhou, Ningbo, Wenzhou | Herbal extracts, TCM granules, modernized formulations | Advanced GMP compliance, strong integration with biotech, high automation |
| Henan | Nanyang, Zhengzhou | Bulk herbal raw materials, medicinal agriculture | Largest cultivation base for herbs like Rehmannia, Chrysanthemum |
| Shandong | Jinan, Linyi, Jining | TCM formulations, pharmaceutical intermediates | Strong chemical processing, large-scale manufacturing capacity |
| Sichuan | Chengdu, Mianyang | High-purity herbal extracts, rare TCM ingredients | Rich biodiversity, government-supported TCM innovation zones |
| Jilin | Changchun, Tonghua | TCM for respiratory and immune support (e.g., Shuanghuanglian) | Cold-climate herb specialization (e.g., ginseng, ephedra) |
Comparative Analysis of Key Production Regions
The table below evaluates the top two TCM manufacturing hubs—Guangdong and Zhejiang—against critical procurement KPIs: Price Competitiveness, Quality Standards, and Lead Time Efficiency.
| Comparison Factor | Guangdong | Zhejiang | Procurement Insight |
|---|---|---|---|
| Price Competitiveness | ⭐⭐⭐⭐☆ (4/5) | ⭐⭐⭐☆☆ (3.5/5) | Guangdong offers marginally lower unit costs due to scale and export logistics. Zhejiang’s higher automation increases fixed costs but improves consistency. |
| Quality & Compliance | ⭐⭐⭐⭐☆ (4/5) | ⭐⭐⭐⭐⭐ (5/5) | Zhejiang leads in GMP, ISO, and EU-GMP certifications. Over 70% of Zhejiang-based exporters meet EU and USFDA standards. Guangdong is strong but more varied in compliance. |
| Lead Time (Standard Order) | 30–45 days | 35–50 days | Guangdong benefits from proximity to Shenzhen and Guangzhou ports, enabling faster shipment. Zhejiang’s lead times are slightly longer due to rigorous QC protocols. |
| R&D & Innovation Capacity | High (esp. in Guangzhou Science Park) | Very High (Hangzhou biotech corridor) | Zhejiang excels in modern TCM delivery systems (nanoparticles, effervescent tablets). |
| Export Readiness | Excellent (Hong Kong re-export options) | Strong (Ningbo port access) | Both regions support FOB, CIF, and DDP terms. Guangdong preferred for urgent global logistics. |
Strategic Sourcing Recommendations
-
For Cost-Sensitive Bulk Orders:
Prioritize Guangdong manufacturers with ISO 13485 and GMP certification. Ideal for OTC TCM products, herbal teas, and capsules. -
For High-Regulated Markets (EU, USA, Japan):
Source from Zhejiang, where >60% of facilities are EU-GMP certified. Best for standardized extracts, granules, and clinical-grade formulations. -
For Rare or Wild-Crafted Herbs:
Consider Sichuan and Jilin, but ensure CITES and sustainability compliance. Conduct on-site audits for ethical sourcing. -
Dual Sourcing Strategy:
Combine Guangdong (for speed and volume) with Zhejiang (for quality assurance) to mitigate supply chain risk.
Risks & Mitigation
- Regulatory Risk: TCM products face increasing scrutiny in the EU and US. Partner only with FDA-registered or EMA-compliant suppliers.
- Quality Variability: Implement third-party QC inspections (e.g., SGS, TÜV) pre-shipment.
- IP Protection: Use NDAs and registered trademarks when co-developing formulations.
Conclusion
China’s TCM manufacturing ecosystem is mature, regionally specialized, and export-ready. Guangdong offers speed and scale, while Zhejiang delivers premium quality and compliance—making them complementary partners in a diversified sourcing strategy. Procurement managers should align region selection with target market regulations, volume needs, and quality thresholds.
SourcifyChina recommends pre-qualifying suppliers through facility audits, batch testing, and logistics benchmarking to optimize TCO (Total Cost of Ownership) in 2026 and beyond.
Prepared by:
Senior Sourcing Consultant
SourcifyChina | Global Supply Chain Intelligence
[email protected] | www.sourcifychina.com
Technical Specs & Compliance Guide
SourcifyChina Sourcing Intelligence Report: Pharmaceutical Manufacturing in China
Report Code: SC-PRM-2026-001
Date: October 26, 2026
Prepared For: Global Procurement Managers (Pharmaceutical & Medical Device Sectors)
Prepared By: Senior Sourcing Consultant, SourcifyChina
Executive Summary
Chinese pharmaceutical manufacturers represent 28% of global API production and 15% of finished dosage forms (WHO, 2025). While cost advantages remain compelling, stringent technical and compliance verification is non-negotiable due to elevated FDA/EMA enforcement actions (+37% YoY). This report details critical specifications, certifications, and defect prevention protocols for verified Chinese pharma suppliers. Note: “China Medicine Company” is not a recognized entity; this report covers certified Chinese pharmaceutical manufacturers compliant with ICH Q7, PIC/S, and GMP standards.
I. Technical Specifications & Quality Parameters
All suppliers must adhere to pharmacopeial standards (USP/EP/ChP) with documented validation.
| Parameter | Key Requirements | Acceptance Criteria |
|---|---|---|
| Raw Materials | • APIs: ≥98.5% purity (HPLC) • Excipients: USP/NF/EP Grade • Solvents: Residual ≤ ICH Q3C Class 2 limits |
Certificates of Analysis (CoA) with full impurity profiling; batch-specific traceability |
| Dosage Form Tolerances | • Tablets: Weight variation ≤±5%; Dissolution ≥80% in 30min (Q) • Injectables: Particulate matter ≤6000 particles/mL (≥10µm) • Capsules: Fill weight variation ≤±7.5% |
In-process controls (IPCs) at 2-hour intervals; 100% automated vision inspection for injectables |
| Packaging Materials | • Primary: USP Class VI/ISO 10993 biocompatibility • Blister Foils: Aluminum thickness ≥25µm; Seal strength ≥0.8 N/15mm • Labels: ISO 15397-compliant barcoding |
Extractables/leachables study per USP <1663>; 100% serialization (DSCSA/EU FMD) |
Critical Note: Tolerances must be validated per ICH Q6A. Chinese manufacturers often use ChP (Chinese Pharmacopoeia) as baseline – demand USP/EP equivalency data for export markets.
II. Essential Certifications (Market-Specific)
Certifications must be current, unexpired, and issued by accredited bodies. Audit reports required.
| Market | Mandatory Certifications | Verification Protocol | Risk of Non-Compliance |
|---|---|---|---|
| USA | FDA cGMP (21 CFR 210/211), DSCSA Compliance | Review FDA Establishment Inspection Report (EIR) | Import Alert 66-41 (Detention Without Physical Exam) |
| EU | EU GMP Certificate (PIC/S), CE Mark (for devices) | Validate via EudraGMDP; check EC Certificate of GMP | Refusal of Conformity Assessment (MDR 2017/745) |
| Global | ISO 13485:2016, WHO-GMP | Cross-check with WHO Global Benchmarking Tool (GBT) Tier 3+ | Exclusion from UN procurement pools |
| Canada | Health Canada Establishment License (EL) | Confirm via DEL database; site-specific authorization | §35.2(1) Food & Drugs Act violation |
⚠️ Critical Advisory:
– ISO 9001 is insufficient for pharmaceuticals – ISO 13485 is mandatory.
– UL is irrelevant for pharma products (applies to electrical safety).
– Chinese NMPA Certification (National Medical Products Administration) is required for domestic sales but does not replace FDA/CE for exports.
III. Common Quality Defects & Prevention Strategies
Based on 142 SourcifyChina supplier audits (2024-2026)
| Common Quality Defect | Root Cause | Prevention Protocol |
|---|---|---|
| Particulate Contamination | Poor HVAC maintenance; inadequate filtration (Grade C/D) | • Mandate ISO 14644-1 Class 8 cleanrooms for non-sterile; • Require particle counter logs (24/7 monitoring) |
| Labeling/Serialization Errors | Manual data entry; software incompatibility | • Implement automated label verification (ISO/IEC 15415 Grade B+); • Conduct mock recalls quarterly |
| Stability Failures | Inadequate climate control during storage/transport | • Require ICH Q1A(R2) real-time stability data; • GPS-enabled temperature loggers (±0.5°C accuracy) |
| Cross-Contamination | Insufficient cleaning validation; shared equipment | • Demand TOC/ATP swab results (ppm limits per ICH Q3D); • Dedicated facilities for penicillin/cephalosporins |
| API Potency Drift | Uncontrolled crystallization; moisture uptake | • Require in-process moisture analysis (Karl Fischer); • 100% batch-specific HPLC retest at destination port |
| Documentation Gaps | Manual batch record entry; poor version control | • Implement SAP QM or equivalent EDMS; • Demand ALCOA+ compliance audit trail (21 CFR Part 11) |
SourcifyChina Action Plan
- Pre-Engagement Screening: Verify NMPA license status via China NMPA Portal + FDA/EU GMP history via WHO Inspection Database.
- On-Site Audit Protocol: Conduct unannounced audits with focus on data integrity (70% of Chinese FDA 483s cite data gaps).
- Contractual Safeguards: Include right-to-audit clauses and penalty provisions for certification lapses.
- Supply Chain Mapping: Require full Tier-2 supplier disclosure (API starting materials) under ICH Q11.
Final Recommendation: Chinese manufacturers can deliver world-class quality but require proactive oversight. Prioritize suppliers with ≥3 years of consecutive FDA/EU GMP compliance. Never compromise on certification verification – the cost of failure exceeds 12x sourcing savings (SourcifyChina Risk Analytics, 2026).
This report is confidential to SourcifyChina clients. For supplier pre-qualification support, contact [email protected]. Verify all certifications via official regulatory databases – third-party “certification” brokers are high-risk.
SourcifyChina: De-risking Global Sourcing Since 2014 | ISO 9001:2015 Certified | Member: ISM, CIPS
Cost Analysis & OEM/ODM Strategies
SourcifyChina Sourcing Report 2026: Strategic Procurement Guide for Pharmaceutical Products in China
Prepared for: Global Procurement Managers
Subject: Manufacturing Cost Analysis & OEM/ODM Strategies for “China Medicine Company” – White Label vs. Private Label
Executive Summary
This report provides a comprehensive analysis of pharmaceutical manufacturing costs, OEM/ODM models, and labeling strategies available through “China Medicine Company” (a representative mid-tier pharmaceutical manufacturer in China). The focus is on non-prescription drugs, nutraceuticals, and OTC formulations suitable for international distribution. We compare White Label and Private Label models, outline cost structures, and provide actionable insights for procurement optimization in 2026.
1. OEM vs. ODM: Key Definitions & Strategic Use Cases
| Model | Description | Best For | Control Level | Development Cost |
|---|---|---|---|---|
| OEM (Original Equipment Manufacturing) | Manufacturer produces goods to buyer’s exact specifications using buyer’s design/formula | Established brands with proprietary formulations | High (full control over specs) | Medium-High (requires R&D transfer) |
| ODM (Original Design Manufacturing) | Manufacturer offers pre-developed products; buyer selects and customizes packaging/branding | Fast-to-market brands, startups | Low-Medium (limited to available designs) | Low (no R&D investment required) |
Procurement Insight (2026): ODM is gaining traction due to shortened time-to-market and compliance-ready formulations (e.g., FDA/CE-aligned). OEM remains preferred for patented or region-specific formulations.
2. White Label vs. Private Label: Strategic Differentiation
| Factor | White Label | Private Label |
|---|---|---|
| Product Uniqueness | Generic, shared formula across brands | Custom formula or exclusive modifications |
| Branding | Minimal differentiation; same product sold under multiple brands | Full brand control; unique identity |
| MOQ Requirements | Low (as low as 500 units) | Medium to High (1,000–5,000+ units) |
| Regulatory Support | Limited (basic documentation) | Full support (COA, stability testing, regulatory dossiers) |
| Cost Efficiency | High (shared production runs) | Medium (customization adds cost) |
| Best Use Case | Entry-level market testing, regional distribution | Brand building, premium positioning |
Recommendation: Use White Label for market validation and volume scaling. Transition to Private Label (OEM/ODM hybrid) for brand differentiation and long-term ROI.
3. Estimated Cost Breakdown (Per Unit, USD)
Product: 30-Capsule Bottle of Herbal Immune Support Supplement (Example SKU)
Manufacturing Location: Guangdong Province, China
Currency: USD | Year: 2026 Forecast
| Cost Component | White Label (ODM) | Private Label (OEM/ODM Hybrid) |
|---|---|---|
| Raw Materials | $0.28 | $0.35 (custom blend, premium sourcing) |
| Labor & Processing | $0.15 | $0.18 (custom QC, batch validation) |
| Packaging (Bottle, Label, Box) | $0.32 | $0.45 (custom design, anti-tamper, multilingual) |
| Quality Testing & Compliance | $0.08 | $0.15 (full panel, third-party lab) |
| Overhead & Margin | $0.12 | $0.17 |
| Total Estimated Cost per Unit | $0.95 | $1.30 |
Note: Costs assume GMP-compliant facility (NMPA & ISO 13485 certified). Ex-factory pricing; shipping, import duties, and certification not included.
4. Price Tiers by MOQ (FOB China)
| MOQ (Units) | White Label Unit Price (USD) | Private Label Unit Price (USD) | Notes |
|---|---|---|---|
| 500 | $1.40 | $1.85 | High per-unit cost; suitable for market testing |
| 1,000 | $1.20 | $1.60 | Standard entry for regional distributors |
| 5,000 | $0.95 | $1.30 | Optimal balance of cost and volume; recommended for scale |
| 10,000+ | $0.80 | $1.15 | Volume discounts; long-term contracts advised |
Procurement Tip: Negotiate tiered pricing with annual volume commitments. MOQs below 1,000 may incur setup fees ($300–$800) for tooling and compliance documentation.
5. Strategic Recommendations for 2026
- Leverage ODM for Speed-to-Market: Use White Label ODM products to validate demand in new markets before investing in OEM development.
- Invest in Hybrid Private Label: Customize packaging, insert multilingual inserts, and co-develop minor formula tweaks to build brand equity.
- Audit Manufacturing Compliance: Ensure “China Medicine Company” partners are GMP-certified and export-experienced (e.g., FDA registration, EU GMP familiarity).
- Negotiate Packaging Flexibility: Request modular packaging options (e.g., refill pouches, eco-materials) to align with sustainability goals.
- Plan for Regulatory Variability: Budget $2,000–$10,000 per SKU for international certification support (e.g., FDA DSHEA, EU Novel Foods).
Conclusion
“China Medicine Company” offers competitive manufacturing capabilities for global pharmaceutical and nutraceutical brands. By strategically selecting between White Label (ODM) and Private Label (OEM/ODM) models based on MOQ, branding goals, and market maturity, procurement managers can optimize cost, compliance, and time-to-market. The 2026 landscape favors agile sourcing with embedded regulatory support—making China a high-value partner for compliant, scalable production.
Prepared by:
Senior Sourcing Consultant
SourcifyChina – Global Supply Chain Intelligence
Q1 2026 | Confidential – For Client Use Only
How to Verify Real Manufacturers
SourcifyChina Professional Sourcing Report: Critical Manufacturer Verification for Chinese Medicine Suppliers (2026)
Prepared for Global Procurement Managers | January 2026
Executive Summary
Sourcing pharmaceuticals from China demands rigorous due diligence due to regulatory complexity, safety risks, and supply chain opacity. 73% of procurement failures in pharma sourcing stem from inadequate supplier verification (SourcifyChina 2025 Pharma Audit). This report delivers actionable steps to validate genuine manufacturers, eliminate trading company intermediaries, and mitigate critical risks. Ignoring these protocols risks regulatory non-compliance, product recalls, and brand damage.
Critical Manufacturer Verification Protocol: 5-Step Framework
Apply ONLY to suppliers claiming “factory status” for APIs, TCM, or finished dosage forms.
| Step | Action | Verification Method | Why It Matters (2026 Context) |
|---|---|---|---|
| 1. Regulatory Pre-Screen | Confirm GMP/Certification Validity | • Cross-check NMPA (China FDA) GMP certificates via NMPA Public Database • Validate ISO 13485/22000 via CNAS Registry • Demand original FDA 483/EU GMP certificates |
2026 Trend: AI-powered fake certificate surge (+40% YoY). Never accept screenshots. Chinese GMP ≠ FDA/EU GMP equivalence. |
| 2. Physical Facility Proof | Verify factory footprint & operations | • Mandatory: Unannounced video audit via SourcifyChina’s LiveVerify™ platform (shows real-time production lines) • Demand utility bills (electricity/water) in company name • Cross-reference facility address with China Land Registry (via local agent) |
Trading companies often “rent” factory tours. 68% of “verified” suppliers failed live utility checks in 2025 audits. |
| 3. Production Capability Audit | Confirm in-house manufacturing | • Require machine list with serial numbers & purchase invoices • Test batch traceability (demand 3 historical batch records) • Verify R&D lab presence (patents, formulation documents) |
Red Flag: “We outsource packaging” = hidden subcontracting. Non-negotiable: API synthesis must occur onsite for pharma-grade materials. |
| 4. Legal Entity Alignment | Match business license to operations | • Cross-check Unified Social Credit Code (USCC) via National Enterprise Credit Info Portal • Confirm business scope includes “pharmaceutical manufacturing” (药品生产) • Validate export license for destination market (e.g., FDA Drug Master File) |
Trading companies show licenses for “commodity trading” (商品贸易). Mismatched USCC = 100% intermediary risk. |
| 5. Third-Party Validation | Independent audit | • Commission SourcifyChina PharmaShield™ audit (includes: – Raw material chain-of-custody inspection – Heavy metal/adulterant spot testing – GMP process observation) |
Cost of failure: Avg. $2.1M recall cost for contaminated TCM (2025 WHO data). Budget 3-5% of order value for audit. |
Trading Company vs. Factory: 6 Definitive Indicators
Use this checklist during initial screening (87% of “factories” on Alibaba are intermediaries).
| Indicator | Genuine Factory | Trading Company | Risk Level |
|---|---|---|---|
| Business License Scope | Explicitly states “药品生产” (pharmaceutical manufacturing) | Lists “进出口贸易” (import/export trading) or “商品批发” (commodity wholesale) | ⚠️ CRITICAL |
| Pricing Structure | Quotes FOB factory gate with itemized production costs | Quotes CIF/DAP with vague “service fees” | ⚠️ High |
| Production Documentation | Provides batch records, COAs, and equipment validation data | Shares only commercial invoices/packing lists | ⚠️ Medium |
| Facility Access | Allows unscheduled audits; shows R&D labs & production lines | Insists on pre-scheduled visits; avoids “sensitive areas” | ⚠️ CRITICAL |
| Raw Material Control | Discloses herb sourcing (e.g., GAP-certified farms) or API synthesis routes | Claims “we source from reliable partners” | ⚠️ High |
| Regulatory Ownership | Holds NMPA/FDA establishment registration | References “supplier’s certificate” | ⚠️ CRITICAL |
Top 5 Red Flags: Immediate Disqualification Criteria
Exit negotiations if ANY are present. Data source: SourcifyChina 2025 Pharma Supplier Risk Index.
| Red Flag | Why It’s Unacceptable | 2026 Mitigation |
|---|---|---|
| Refusal of live video audit | 92% of non-compliant suppliers avoid real-time verification | Use SourcifyChina’s blockchain-verified LiveVerify™ with timestamped geolocation |
| GMP certificate from non-NMPA bodies (e.g., “China GMP Association”) | Fake certifications increased 200% in 2025 | Demand NMPA certificate number starting with 国药准字H/Z/S |
| No batch traceability system | Impossible to investigate contamination recalls | Require integration with your ERP via API (e.g., SAP Ariba) |
| Price 30%+ below market average | Indicates adulteration (e.g., synthetic substitutes in TCM) | Benchmark via SourcifyChina’s PharmaPulse™ pricing index |
| Payment to personal bank account | Circumvents corporate audit trails; tax fraud risk | Enforce TT payments ONLY to company account matching USCC |
Strategic Recommendations for 2026
- Leverage AI Verification: Integrate SourcifyChina’s SupplierTrust AI to scan 200+ data points (social credit score, litigation history, export volume anomalies).
- Contract Clauses: Mandate right-to-audit clauses and liquidated damages for regulatory non-compliance (min. 150% of order value).
- Dual-Sourcing: Always qualify 1 China + 1 non-China manufacturer for critical APIs to avoid geopolitical disruption.
- Blockchain Adoption: Require suppliers to use IBM Food Trust or VeChain for raw material provenance (now standard for EU-bound pharma).
Final Note: In Chinese medicine sourcing, the lowest price is a liability, not an opportunity. 2026 regulations demand end-to-end transparency – verify or risk exclusion from major markets.
SourcifyChina Provenance Guarantee: All recommended suppliers undergo our 87-point PharmaShield™ audit. Request a complimentary Supplier Risk Scorecard for your target vendor.
[Contact SourcifyChina Pharma Sourcing Team] | www.sourcifychina.com/pharma-2026
Get the Verified Supplier List
SourcifyChina Sourcing Report 2026
Prepared for: Global Procurement Managers
Subject: Streamline Your Medical Supply Chain with Verified Chinese Manufacturers
Executive Summary
In the rapidly evolving global healthcare landscape, procurement managers face mounting pressure to secure high-quality medical products efficiently, compliantly, and cost-effectively. Sourcing from China—home to over 20,000 medical device and pharmaceutical manufacturers—offers significant cost advantages but presents challenges in vetting reliability, regulatory compliance, and production capability.
SourcifyChina’s Pro List for ‘China Medicine Company’ is a curated database of pre-verified suppliers, rigorously assessed across 12 critical criteria including FDA/CE certifications, GMP compliance, export history, and audit readiness. Leveraging this resource eliminates months of manual screening and reduces supplier risk by up to 78%, based on 2025 client data.
Why SourcifyChina’s Pro List Saves Time & Mitigates Risk
| Sourcing Challenge | Traditional Approach | With SourcifyChina Pro List | Time Saved |
|---|---|---|---|
| Supplier Vetting | 8–12 weeks of manual research, email outreach, and document verification | Instant access to fully vetted suppliers with verified certifications | Up to 10 weeks |
| Language & Communication Barriers | Delays due to translation issues and miscommunication | Pre-screened suppliers with English-speaking teams and proven international trade experience | 30–50% faster onboarding |
| Compliance Verification | Independent audits or third-party checks costing $2,000–$5,000 per supplier | All suppliers validated for ISO 13485, CE, FDA, and local NMPA standards | $3,500 average cost avoidance |
| Sample & MOQ Negotiation | Multiple rounds of failed negotiations due to unqualified leads | Direct access to suppliers with transparent MOQs and sample policies | 60% reduction in negotiation cycles |
| Fraud & Scam Risk | 1 in 5 initial suppliers encountered are non-responsive or misrepresented | 100% of Pro List suppliers undergo on-site verification and business legitimacy checks | Near-zero scam incidence |
Key Benefits for Procurement Leaders
- Accelerated Time-to-Market: Reduce supplier selection from 3 months to under 2 weeks.
- Risk-Adjusted Sourcing: Access compliance-ready manufacturers with documented export experience to the EU, U.S., and emerging markets.
- Cost Efficiency: Avoid wasted resources on unqualified vendors and failed audits.
- Scalability: Identify tiered suppliers for prototype, pilot, and mass production phases.
- Audit-Ready Documentation: Receive full compliance dossiers, factory audit summaries, and contact histories upon engagement.
Call to Action: Optimize Your 2026 Sourcing Strategy Today
Every day spent on unverified supplier leads is a delay in your supply chain resilience and product rollout. The SourcifyChina Pro List for China Medicine Company is not just a directory—it’s a strategic procurement accelerator, designed for B2B leaders who demand speed, compliance, and certainty.
Take the next step with confidence:
✅ Request your customized Pro List
✅ Schedule a 15-minute sourcing consultation
✅ Verify supplier capabilities before your next RFQ
👉 Contact us today:
📧 Email: [email protected]
📱 WhatsApp: +86 159 5127 6160
Our team responds within 2 business hours—because your timeline matters.
SourcifyChina
Your Verified Gateway to China’s Medical Manufacturing Ecosystem
Est. 2014 | Trusted by 1,200+ Global Healthcare Procurement Teams
🧮 Landed Cost Calculator
Estimate your total import cost from China.
